Objective: To determine the molecular differences between iMCD-thrombocytopenia, anasarca, fevers, reticulin myelofibrosis, organomegaly (TAFRO), and iMCD-not otherwise specified (NOS).
Methods: CD4-positive T cells were isolated from two iMCD-TAFRO and two iMCD-NOS patients for RNA sequencing comparison. Serum proteins of two iMCD-TAFRO and four iMCD-NOS patients were comprehensively analyzed to identify pathogenesis-associated proteins. IGFBP-1 protein, extracted from serum analysis, was compared to healthy controls, iMCD, systemic lupus erythematosus, and rheumatoid arthritis patients.
Results: RNA sequencing of CD4-positive T cells revealed enhanced mTOR-related signaling in iMCD-TAFRO compared to iMCD-NOS. Comprehensive serum analysis found IGFBP-1 linked to iMCD pathogenesis, significantly higher in iMCD-TAFRO. This protein may be elevated in patients with iMCD caused by an enhanced mTOR pathway.
Conclusion: The mTOR pathway is suggested to be activated in iMCD-TAFRO compared to iMCD-NOS, which may elevate the protein IGFBP-1. This protein may be a biomarker to distinguish iMCD-TAFRO from iMCD-NOS.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clim.2023.109798 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Transcriptome analysis of the cytokine storm-related genes among the subtypes of idiopathic multicentric Castleman disease.
J Clin Exp Hematop
December 2024
Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences, Okayama, Japan.
Article Synopsis
- Idiopathic multicentric Castleman disease (iMCD) is a subtype of Castleman disease that is not linked to KSHV/HHV8 and is categorized into three types: iMCD-IPL, iMCD-TAFRO, and iMCD-NOS.
- The primary treatment is IL-6 inhibitors, yet patients with iMCD-TAFRO and NOS often show resistance, indicating the influence of other cytokines in their pathology.
- A transcriptome analysis revealed increased expression of various cytokine-related genes in iMCD-TAFRO/NOS, suggesting enhanced inflammatory signaling pathways, particularly the JAK-STAT and MAPK pathways, contributing to a potential cytokine storm.
Peculiar hyper vascular manifestations in idiopathic multicentric castleman disease without tafro syndrome: a case report.
Ann Hematol
October 2024
Dr. Ruth K.M. Pfau, Civil Hospital, Karachi, Pakistan.
Background: Castleman disease affects lymph nodes with abnormal cell growth. It has unicentric (single node) Castleman disease (UCD) and multicentric (multiple nodes) Castleman disease (MCD) forms. MCD is systemic, with diverse symptoms, necessitating systemic treatment.
View Article and Find Full Text PDFIdiopathic multicentric Castleman disease with marrow fibrosis and extramedullary hematopoiesis.
Eur J Haematol
December 2024
Division of Hematology, Dalhousie University, Halifax, Nova Scotia, Canada.
Background: Idiopathic multicentric Castleman disease (iMCD) is a rare inflammatory disorder mediated by excessive proinflammatory cytokine signaling, most notably by interleukin 6 (IL-6). IL-6-induced extramedullary hematopoiesis (EMH) has been reported in murine models of iMCD. Herein we present four cases of iMCD with EMH in humans.
View Article and Find Full Text PDFBiomarkers and Signaling Pathways Implicated in the Pathogenesis of Idiopathic Multicentric Castleman Disease/Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis, Renal Insufficiency, and Organomegaly (TAFRO) Syndrome.
Biomedicines
May 2024
Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan.
Idiopathic multicentric Castleman disease (iMCD) and TAFRO syndrome present a variety of symptoms thought to be caused by excessive inflammatory cytokines and chemokines, but the underlying mechanisms are unknown. iMCD is broadly classified into two types: iMCD-NOS and iMCD-TAFRO, which have distinct laboratory findings, pathological features, and responses to treatments. It is thought that iMCD-NOS, particularly the IPL type, responds favorably to IL-6 inhibitors due to its IL-6-centric profile.
View Article and Find Full Text PDFTAFRO Syndrome: A Syndrome or a Subtype of Multicentric Castleman Disease?
Biomedicines
March 2024
Department of Hematology, Niigata City General Hospital, Niigata 950-1197, Japan.
TAFRO (thrombocytopenia, anasarca, fever, reticulin fibrosis of bone marrow/renal dysfunction, organomegaly) syndrome is a systemic inflammatory disorder of unknown etiology. It has been recognized as a subtype of idiopathic multicentric Castleman disease (iMCD), and the international diagnostic criteria for iMCD-TAFRO require a lymph node histopathology consistent with iMCD. Furthermore, TAFRO syndrome is defined as a heterogeneous clinical entity caused by underlying diseases such as malignancy, autoimmune diseases, or infections.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!